



August 8, 2022

**U.S. Patent and Trademark Office Issues a Non-Final Rejection of the  
Morris, Pompa, Philips, et. al. U.S. Patent Application claims**

**FOR IMMEDIATE RELEASE**

Metron Nutraceuticals, LLC (“Metron”, Cleveland, OH, USA) announced today that the United States Patent and Trademark Office (USPTO) issued a **non-final rejection** of the **Morris, Pompa, Philips, et. al. U.S. Patent Application claim**.

From May 2015, until October 2017, Metron Nutraceuticals produced **CytoDetox**. **CytoDetox** was Metron’s professional strength detox dietary supplement formulation based on Metron’s patented<sup>1, 2, 3</sup> water solution of water-soluble zeolite fragments technology. The commercial name **CytoDetox** was not owned by Metron.

For the distribution of **CytoDetox** to licensed Health Care Professionals (HCPs) in the US, Metron entered into an Exclusive Distribution Agreement with **180 Degree Solutions** (180) owned by **Warren Phillips and Dan Pompa**.

After 180 breached the Exclusive Distribution Agreement, Metron terminated the EDA on **October 6, 2017**. After the termination of the Metron – 180 EDA, Metron never produced **CytoDetox** again.

From November 2017 until today, Metron’s professional strength detox dietary supplement formulation based on Metron’s patented<sup>1, 2, 3</sup> water solution of water-soluble zeolite fragments technology is available to licensed HCPs under Metron’s owned and Registered commercial name **ClearDetox Pro**<sup>®</sup>.

On October 30, 2017, 24 days after Metron’s termination of the Metron – 180 EDA, 180 filed a civil complaint against Metron with several serious allegations.

Metron counterclaimed against 180. A jury trial conducted in Cleveland, OH on February 2020 resulted in an eight out of eight, unanimous jury verdict in favor of Metron. The jury awarded 180 no money for any of its claims against Metron. On the other hand, the jury found 180 liable for breach of contract.

**CytoDetox** is currently available for purchase by Revelation Health, LLC, a company owned by Warren Phillips and it is advertised as **“Patent Pending”** based on a Patent Application of purported “inventors” **Shayne K, Morris, Firas**

**S. Harb, Warren P. Phillips, and Daniel Pompa and Assigned to Revelation Health, LLC, (US 2021/0032115 – Morris, Pompa, Phillips, et. al. Patent Application).**

On **July 8, 2021**, Metron filed a **Third-Party Submission** to the United States Patent and Trademark Office (USPTO) challenging the patentability of the **Morris, Pompa, Philips, et. al. Patent Application**. Metron requested the rejection of all six claims of the **Morris, Pompa, Phillips, et. al. Patent Application** based on Metron's Patents<sup>1, 2, 3</sup> for water-soluble zeolite fragments and other Patent and non-Patent previous publications by others.

On **June 8, 2022**, the listed "inventors" **Morris, Pompa, Phillips, et. al.** voluntarily withdrew five claims and amended one claim of their Patent Application.

On July 20, 2022, the United States Patent and Trademark Office (USPTO) issued a non-final rejection of the single remaining claim of the **Morris, Pompa, Phillips, et. al. U.S. Patent Application** as being **unpatentable**.

About Metron Nutraceuticals, LLC

Metron Nutraceuticals, LLC, formed by Dr. Nikolaos Tsirikos-Karapanos in 2014 in Cleveland, Ohio, is a pioneer in the formulation and manufacture of specialized forms of natural mineral compositions for various wellness applications. Metron's experience, innovative technology formulations, and specialized methods of manufacture have culminated in three U.S. Patents (U.S. Patent No. **9,629,874**<sup>1</sup>, U.S. Patent No. **10,206,948**<sup>2</sup>, and U.S. Patent No. **10,828,324**<sup>3</sup>), one Patent in Japan (No. **6490807**), one Patent in Russia (No. **2744886**), one Patent in Korea (No. **10-2393143**) as well as numerous additional International Patent Pending Applications.